Abstract:Oral probiotics have emerged as a promising therapeutical strategy for effectively managing ulcerative colitis (UC) in the world. The existing researches successfully preserve probiotic viability in the upper gastrointestinal tract, but they fall short in achieving precise release profile and effective colonization of probiotics at the site of colitis in colon as well as the understanding of therapeutic mechanism with suboptimal efficacy. This constraint poses a significant barrier to rational design and effective development of oral probiotic system. Here, we fabricate an orally layered-by-layered probiotic (Escherichia coli Nissle 1917, EcN) system (so-called CML@EcN) based on carboxymethyl modified lignin (CML) which can significantly protect EcN in gastric and small intestinal microenvironment and efficiently control release EcN in colon. Interestingly, the release and proliferation process of EcN in the colon are detected and can be modeled as a plug-flow mode. We derive a mathematical expression that highly matches the experimental results, providing a theoretical basis for quantitatively calculation of the release process. Furthermore, CML@EcN significantly alleviates symptoms in dextran sulfate sodium (DSS)-induced UC mice by modulating the multiple organ immune disorder and gut microbiota (GM)/metabolites profile as well as reconstructing the colon barrier. Importantly, we explore the mechanism of immune homeostasis regulation via metabolism from GM. Moreover, the CML armour is excreted and would not influence the process. This work not only reports a novel oral therapeutic for UC treatment with high efficacy as well as the exploration of mechanism between GM and immune homeostasis, but also provides a general approach to engineer probiotics for oral administration.

Breaking barriers: bacterial-microalgae symbiotic systems as a probiotic delivery system

Microalgal Biomass-Assisted Delivery of Probiotics for Modulation of Gut Homeostasis and Alleviation of Intestinal Inflammation

A Rapid Screening Method of Candidate Probiotics for Inflammatory Bowel Diseases and the Anti-inflammatory Effect of the Selected Strain Bacillus Smithii XY1

Microfluidics-Derived Microparticles with Prebiotics and Probiotics for Enhanced in Situ Colonization and Immunoregulation of Colitis.

Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery

Microfluidic-based Multifunctional Microspheres for Enhanced Oral Co-Delivery of Probiotics and Postbiotics

Multishell Colloidosome Platform with Sequential Gastrointestinal Resistance for On-Demand Probiotic Delivery.

Engineering microbial fermentation-based delivery carriers capable of controlling drug release for inflammatory bowel disease therapy

Modified montmorillonite armed probiotics with enhanced on-site mucus-depleted intestinal colonization and H2S scavenging for colitis treatment

Biohybrid microrobots regulate colonic cytokines and the epithelium barrier in inflammatory bowel disease

Bioorthogonal conjugation and responsive nanocoating of probiotics for inflammatory bowel disease

Modified Montmorillonite Armed Probiotics with Enhanced On-Site Mucus-Depleted Intestinal Colonization and H2S 2 S Scavenging for Colitis Treatment

Modified Prebiotic-Based "Shield" Armed Probiotics with Enhanced Resistance of Gastrointestinal Stresses and Prolonged Intestinal Retention for Synergistic Alleviation of Colitis

Nanoprobiotics for Remolding the Pro-inflammatory Microenvironment and Microbiome in the Treatment of Colitis

Orally surface engineered probiotic system for ulcerative colitis therapy via modulating gut microbiota and immune homeostasis

The single-cell modification strategies for probiotics delivery in inflammatory bowel disease: A review

Probiotic‐inspired nanomedicine restores intestinal homeostasis in colitis by regulating redox balance, immune responses, and the gut microbiome

Physiologically Inspired Mucin Coated Escherichia coli Nissle 1917 Enhances Biotherapy by Regulating the Pathological Microenvironment to Improve Intestinal Colonization

Probiotics Armed with In Situ Mineralized Nanocatalysts and Targeted Biocoatings for Multipronged Treatment of Inflammatory Bowel Disease

Orally Hierarchical Targeting Delivery Systems Relieve Colitis by Protecting Host Mitochondria and Modulating Gut Microbiota

Responsively Degradable Nanoarmor-Assisted Super Resistance and Stable Colonization of Probiotics for Enhanced Inflammation-Targeted Delivery